ClinicalTrials.gg
RecruitingNCT07449832SPELHUpdated Nov 13, 2026

Sperm Epigenome in Hodgkin Lymphoma

An interventional study of Additional semen samples in Hodgkin Disease Lymphoma, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Prevention

How we know

Updated Nov 13, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Hodgkin Disease with a site in France — 6 open to participants now, 13 under way, 2 of them phase 3. Hodgkin Disease · France.

Planned enrollment
48th of 59
50 · median 106
Started
2026
the only one that year
No phase
13 of 72
2 open now
Primary completion
2030-11
later than 11 of 12 live
Registered
72nd of 72
by date
Lead sponsor
3 of 72
Rennes University Hospital

Among the 72 studies in Hodgkin Disease with a site in France, this one is the 48th largest by planned enrollment of the 59 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 72nd registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

6 of the 72 studies in Hodgkin Disease with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Hodgkin Disease with a site in France, or all of them as a file.
02

Study summary

Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.

We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.

Read the detailed description

Advances in cancer treatments are raising new health questions for young survivors of the disease. Cancer itself and DNA-targeted treatments can have long-term effects on reproductive health. In men, spermatogenesis may remain impaired even years after recovery, with consequences for fertility and the health of offspring. It is important to note that sperm production can recover after cancer remission. However, men are advised to wait at least one year after the end of treatment before attempting natural conception, as gamete quality may influence reproductive capacity and offspring health. Yet, regardless of the mode of conception (natural or assisted reproduction), the question of whether a history of cancer and its treatment may affect the health of their offspring remains a fundamental issue that has not yet been clearly answered. In-depth studies are needed for this growing population of young cancer survivors who wish to have healthy children.

Where possible, the use of alkylating agents-known for their long-term systemic harmful effects-is being reduced, and less reprotoxic compounds, such as anthracyclines, are favored. Anthracyclines are widely used to treat various cancers prevalent in young men with a favorable survival prognosis and are classified as weakly reprotoxic (i.e., causing a temporary reduction in sperm count). However, they are suspected of having long-term effects on sperm chromatin and epigenome. The establishment of the sperm epigenome is a complex process resulting from multiple nuclear events during spermatogenesis, including chromatin remodeling and compaction that occur during spermiogenesis. These represent windows of opportunity for alteration by xenobiotics. Furthermore, genomic regions undergoing chromatin rearrangements may be more vulnerable to alterations; if these regions are located on key genes for embryonic development or fetal programming, they may predict adverse effects on offspring. In fact, emerging evidence suggests that sperm epigenetic marks could be used clinically to predict fertility and male-mediated developmental toxicity.

Here, we focus on young men with Hodgkin lymphoma (HL), one of the most commonly diagnosed malignant tumors at a young age, with a good prognosis and low risk of relapse, and for which treatment is well characterized using an anthracycline-containing protocol: doxorubicin. This pathology thus represents a large and relevant population of young cancer survivors who will consider parenthood after cancer. Due to interindividual variability, human studies aiming to determine the effects of chemotherapy must be able to compare samples before and after treatment in the same individual. Such published prospective longitudinal studies are rare and often include very few cases, as they require substantial resources, strong links between oncology and reproduction services, and the ability to follow patients over time, even after the end of oncological treatment. A (non-longitudinal) study of the long-term effects of HL treatments demonstrated persistent abnormalities in chromatin structure and DNA integrity. In the study proposed here, we will analyze epigenetic modifications in sperm from HL patients and their evolution after chemotherapy. We hypothesize that HL and its treatment induce persistent alterations up to 2 years after remission.

03

Conditions studied

  • Hodgkin Disease Lymphoma

Browse trials for

Keywords

  • epigenetic
  • chemotherapy
  • male gametes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18 to 45 years
  • Diagnosed with Hodgkin lymphoma
  • Treatment-naïve to any cytotoxic therapy
  • Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD
  • Beneficiaries of the French social security system
  • Not opposed to participating in research

Exclusion criteria

Exclusion Criteria:

  • Patient receiving abdominal radiotherapy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Epigenetic analysis in semen samples

    30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes

    Other: Additional semen samples

Interventions

  • OtherAdditional semen samples

    5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis.

06

What researchers measure

Primary outcomes

  1. Alterations in DNA methylation patterns in spermatozoa

    Sperm analysis : Methyl-C Capture Sequencing (MCC-seq)

    Time frame: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

  2. Alterations of histone 3 H3k4me3 retention sites in spermatozoa

    Sperm analysis : chromatin immunoprecipitation followed by sequencing (ChIP-seq)

    Time frame: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

Secondary outcomes

  1. Spermogram exam

    Spermogram examination

    Time frame: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

  2. Identification of known environmental factors impacting spermatogenesis

    Patient questionnaire

    Time frame: Month 24 after chemotherapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Nov 2030, 48 months after the start.

Of 50 non-industry interventional studies with no phase under Hodgkin Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 128. This study's planned 48 months is above that.

Counting every sponsor, half of 53 studies reached it within 42 months; a quarter within 29 and three quarters within 128.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jun 2026 → Nov 2026, primary completion Jan 2030 → Nov 2030 and completion Jan 2030 → Nov 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Mar 4, 2026
StartActual
Nov 9, 2026was Jun 2026
Primary completionEst.
Nov 2030was Jan 2030
CompletionEst.
Nov 2030was Jan 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
Centre Hospitalier Universitaire de Rennes is now Recruiting
Nov 13, 2026
Start date
Jun 1, 2026→Nov 9, 2026 (actual)
Nov 13, 2026
Primary completion
Jan 1, 2030→Nov 2030
Nov 13, 2026
Study completion
Jan 1, 2030→Nov 2030
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    Centre Hospitalier Universitaire de Rennes is now Recruiting
    Start date Jun 1, 2026→Nov 9, 2026 (now actual)
    Primary completion Jan 1, 2030→Nov 2030
    Study completion Jan 1, 2030→Nov 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07449832
Collaborators
Institut National de la Recherche Scientifique - Centre Armand Frappier Santé Biotechnologie
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Nov 9, 2026
Primary completion
Nov 2030 (estimated)
Completion
Nov 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Tony MARCHAND, MD, PhD
Contact
tony.marchand@chu-rennes.fr
02 99 28 42 91 ext. +33
Célia RAVEL, MD, PhD
Contact
celia.ravel@chu-rennes.fr
02 99 26 59 16 ext. +33
Géraldine DELBES, PhD
study chair · Institut National de la Recherche Scientifique (INRS), Québec, Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion